ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy ...

At the turn of the 20th century, bovine tuberculosis, a bacterial disease that infected cows and spilled over to humans via milk ran rampant in France. Today, a weakened form of that same ...

Liam Gaughan is a film and TV writer at Collider. He has been writing film reviews and news coverage for ten years. Between relentlessly adding new titles to his watchlist and attending as many ...

After reports of violence outside aid sites in Gaza, the Wall Street Journal analyzed satellite imagery, video and witness testimony, and found that the U.S.-led, Israel-backed process has led to ...

One of the world’s largest consulting firms has fired two rogue employees who defied a company prohibition and led a “small, off-the-books team” involved in crunching the numbers on the costs of ...

The Trump administration Thursday asked McKinsey, BCG and several other firms with billions of dollars in federal contracts to justify their work—and suggest cost cuts. The General Services ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Michael ends up finding himself trapped on the roof of his school with the Agents closing in on ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...

Boosting survival in advanced urothelial carcinoma: The power of CBM588 probiotic and pembrolizumab combination. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.

Mitomycin C can be a cost-effective alternative to BCG as intravesical treatment for intermediate-risk nonmuscle-invasive bladder cancer at a time when BCG is in short supply. Mitomycin C has ...